Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.60 |
| ▸ | ACHE | P22303 | 12/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | NAAA | Q02083 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28440301 | 0.98 | EPHX1 (0.63) | EPHX1ACHEMEN1FAAHMAPK1 | |
| SCHEMBL8382659 | 0.94 | EPHX1 (0.52) | EPHX1ACHEMEN1FAAHMAPK1 | |
| SCHEMBL8385048 | 0.85 | TSHR (0.49) | EPHX1ACHEMEN1FAAHMAPK1 | |
| SCHEMBL30663333 | 0.84 | ACHE (0.51) | EPHX1ACHE | |
| SCHEMBL2494231 | 0.83 | EPHX1 (0.55) | EPHX1ACHEFAAHNAAA | |
| SCHEMBL2494230 | 0.83 | EPHX1 (0.55) | EPHX1ACHEFAAHNAAA | |
| SCHEMBL11404671 | 0.83 | EPHX1 (0.59) | EPHX1ACHENAAA | |
| SCHEMBL13176199 | 0.82 | EPHX1 (0.46) | EPHX1ACHEMEN1FAAHMAPK1 | |
| SCHEMBL16124605 | 0.82 | EPHX1 (0.58) | EPHX1ACHEFAAHNAAA | |
| SCHEMBL7770681 | 0.82 | EPHX1 (0.58) | EPHX1ACHEFAAHNAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2003097603-A1 | PROCESS FOR THE PREPARATION OF HIGHLY PURE TORSEMIDE | FINETECH LABORATORIES LTD. (IL) | 2003-11-27 | — | — | WO | claimed |
| WO-2023083201-A1 | AMINOPYRAZOLE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海拓界生物医药科技有限公司 | 2023-05-19 | — | — | WO | disclosed |
| US-20210206744-A1 | BENZIMIDAZOLE COMPOUNDS AS AGRICULTURAL CHEMICALS | REDAG CROP PROT LTD (GB) | 2021-07-08 | — | — | US | disclosed |
| WO-2003097603-A1 | PROCESS FOR THE PREPARATION OF HIGHLY PURE TORSEMIDE | FINETECH LABORATORIES LTD. (IL) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210206744-A1 | BENZIMIDAZOLE COMPOUNDS AS AGRICULTURAL CHEMICALS | BRI3BP, CYP3A4, CYP3A5 | EPHX1 2786/4885ACHE 191/4885MEN1 3277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.